CDKN2A and meningioma: The 2021 WHO Classification includes molecular features, that is, pTERT mutation and CDKN2A/B HoDe, in meningioma grading for the first time, thus allowing the identification of some meningiomas devoid of malignant histological features but prone to a higher recurrence risk.